IDWeek 2016 was held in New Orleans from October 26th through 31st. This is a joint meeting of groups like the Infectious Disease Society of America and the HIV Medicine Association which is an association of the HIV doctors.
There were a number of interesting PrEP (pre-exposure prophylaxis) presentations at the International AIDS Conference, which was held in Durban, South Africa, from July 18th to 22nd, 2016. Scott McCallister from Gilead presented 2016 CDC HIV transmission risk data in the U.S., an overview of 32 international studies of FTC/TDF (Truvada) usage for PrEP since it was licensed in the U.S. in 2012, and U.S. PrEP utilization data. Truvada, which is part of a cocktail regimen for people with HIV has demonstrated as much as a 90% effective rate in reducing the risk of HIV transmission when it is taken […]
The bi-annual International AIDS Society’s (IAS) Conference on HIV Pathogenesis was held in Vancouver, Canada from July 19-22, 2015. There were a number of PrEP (Pre-Exposure Prophylaxis) presentations that continue to describe the use of PrEP in MSM.
Two PrEP trials at CROI show an 86% reduced risk of HIV transmission in MSMs This year’s Conference on Retroviruses and Opportunistic Infections (CROI 2015) was held in Seattle, Washington, from February 23 to 26. Arguably, the most exciting news this year involves three pre-exposure prophylaxis (PrEP) studies.
The International AIDS Society’s (IAS) Towards a Cure Workshop was held in Melbourne, Australia on July 19-20, 2014, immediately before the 20th International AIDS Conference (IAC). This article will provide highlights of the “Cure” Symposium. I have included numerous presentations from Martin Delaney CARE Collaboratory (MDC) researchers funded by the National Institute for Allergy and Infectious Diseases to find a “Cure” for HIV. I am the co-coordinator of the CARE Collaboratory’s Community Advisory Board, one of the three MDCs . As a member of CARE, I am more familiar with their “kick and kill” virology work that I will be […]